Eli Lilly has walked away from PBS listing for Mounjaro. Here's what it means for your costs, and practical ways to protect an expensive self-funded medication.
Download on the App StoreNo. Mounjaro (tirzepatide) is not currently PBS-listed in Australia as of July 2026. The November 2024 PBAC application was not recommended, and the listing process has ceased. All patients pay full private price, typically $250–$700 per month depending on dose.
Without a PBS listing, Mounjaro is a private prescription. Patients typically pay $250–$700 per month depending on the dose. There is no government subsidy available.
Because Mounjaro has no PBS subsidy, Chemist Warehouse and every other Australian pharmacy sell it as a private script at broadly similar prices, roughly $350/month at 5mg up to $600–$700/month at the highest doses. Prices vary a little between pharmacies and change over time, so it's worth ringing ahead. Whichever pharmacy you use, the bigger saving is not wasting a dose or letting a script expire. That's what a medication tracker protects.
No. Mounjaro is not currently PBS-listed for any indication in Australia, including weight loss and type 2 diabetes. All prescriptions are private and patients pay the full market price, typically $250–$700 per month.
No. Mounjaro is not currently PBS-listed, so all costs are private prescription costs and do not count toward the PBS Safety Net.
Most PBS prescriptions for chronic conditions like diabetes come with 5 repeats, providing a 6-month supply. MediRemind tracks these repeats and reminds you when you're on your last one.